

1 **Full Title:** Risk of Heart Failure among Individuals with Metabolic Syndrome Components

2 **Corresponding Author:**

3 Rajan Lamichhane, PhD

4 Assistant Professor

5 Department of Clinical and Translational Sciences (DCTS)

6 Joan C. Edwards School of Medicine

7 Marshall University 1600 Medical Center Drive, Room 256

8 Huntington, WV 25701

9 ☎ 304-691-8648

10 lamichhaner@marshall.edu

11 **Co-authors:**

12 1. Vijay Bharti, MD Student

13 Joan C Edwards School of Medicine

14 Marshall University

15 bharti2@marshall.edu

16

17 2. Aarshi R Lamichhane

18 Hurricane High School

19 rclam123@gmail.com

20

21 3. Kamran Zaheer, DO

22 Assistant Professor, Internal Medicine

23 Joan C Edwards School of Medicine

24 Marshall University

25 zaheer@marshall.edu

26 **Short Title:** Metabolic Syndrome Components and Risk of Heart Failure

27

28

29

30

31

32

33 **Abstract**

34 Metabolic dysfunction of metabolic syndromes (MetS) has been widely reported to be a
35 significant risk factor for heart failure (HF). While this interaction is well studied, what
36 combinations of MetS factors pose the greatest risk for HF are not well defined. We hypothesize
37 that some components of MetS are of higher risk of HF compared to others. We explored the
38 relationship between the independent components of MetS and their combinatory effect on the
39 risk of HF. All metabolic syndrome components except hypertriglyceridemia were significant
40 individually (P-value<0.001), while hypertension (HTN) and diabetes or insulin resistance (IR)
41 had the higher risk of developing heart failure when taken collectively. The odds of heart failure
42 among the individuals who had HTN and IR was 7.7 times those who didn't have any MetS
43 components. We observed the additive effect of number of metabolic components on HF, for the
44 individuals who had only one MetS symptom, the odd of HF was 5.4 time compared to those
45 who didn't have any of MetS symptoms. Similarly, these odds of HF were 6.4 and 7.4 times for
46 those who had at least 2 or at least 3 symptoms respectively. Even though obesity is a significant
47 risk factor for cardiovascular diseases, we found the protective effect of obesity on heart failure,
48 which is an interesting result and needs further investigation.

49 **Keywords:** Retrospective case-control study, metabolic syndrome, heart failure, obesity,
50 hypertension, insulin resistance, risk analysis

51

52

53 **Non-standard Abbreviations and Acronyms**

54 CVD - CardioVascular Disease

55 MI – Myocardial Infaction

56 MetS - Metabolic Syndrome

57 IR- Insulin Resistance

58 HTN – Hypertension

59 HG – HypertriGlyceridemia

60 HDL – Low High-Density Lipoprotein

61 HF – Heart Failure

62 BMI – Body Mass Index

63 IHD - Family history of Ischemic Heart Disease

64 CAD - History of Coronary Artery Disease

65 OR – Odds Ratio

66 AR – Attributable Risk

67 HFpEF - Heart Failure with preserved Ejection Fraction

68 HFrEF – Heart Failure with reduced Ejection Fraction

69 HbA1c – Hemoglobin A1c

70

71 **Introduction**

72 Cardiovascular disease (CVD) is the leading cause of death in the United States ¹ and CVD is the
73 most common cause of myocardial infarction (MI). An MI occurs every 40 seconds; every year,
74 about 805,000 people in the United States have an MI ² accounting for 13.4% of all registered
75 deaths in 2018 ¹.

76 Metabolic Syndrome (MetS) is associated with numerous adverse health outcomes including
77 CVD ³⁻⁹. MetS is comprised of five components—insulin resistance (IR), hypertension (HTN),
78 hypertriglyceridemia (HG), low high-density lipoprotein cholesterol (HDL), and obesity ¹⁰.

79 Several research studies focused on the relationship between MetS and Heart Failure (HF) ¹¹⁻¹³,
80 but limited work shows the association between MetS factors and HF. The components of MetS
81 have been linked to an increased risk for HF ¹⁴⁻¹⁶; however, their interactions are not defined. It
82 is not common to find individuals with only a single component of MetS, rather, they present
83 together as a constellation often unique to the individual. It is therefore important to study the
84 simultaneous effect of these components on HF as they overlap among the same group of
85 people. Understanding the risk of HF among each of the MetS components could help direct
86 screening and treatment. In our study, we intend to identify the MetS components and their
87 respective combinations that create the highest risk of developing HF.

88 Our study is focused on the Appalachian population as this region has a disproportionately
89 higher incidence of HF compared to the rest of the United States ¹⁷. Also, Appalachia performs
90 worse than the nation in several health indicators. According to the Appalachian Regional

91 Commission report ^{18,19}, 7 out of the 10 leading causes of death in the United States, including
92 CVD, are higher in the Appalachian Region compared to the nation.

93 This study of the rural Appalachian population is important to understand the mechanism of
94 HF among this medically underserved population. The presence of comorbidities, like smoking
95 and obesity, significantly affects the long-term morbidity and mortality of patients with HF ²⁰.

96 Population studies have shown that metabolic syndrome increases the risk of developing HF
97 and this effect is mediated by insulin resistance. However, obesity is a key component in
98 metabolic syndrome and a customary partner of insulin resistance because it is protective in
99 patients with established HF, although insulin resistance confers an increased risk of dying

100 from HF. Obesity, a key element of MetS, is often present alongside insulin resistance. In

101 patients with HF, obesity can offer a degree of protection, although insulin resistance is

102 associated with an increased risk of mortality from HF. This phenomenon is called the "obesity

103 paradox" accounting for the complexity of the relationship between HF and MetS ²¹. This

104 paradoxical relationship between MetS and HF should further be investigated to understand

105 the relationship between MetS and HF. Our study aims to investigate this complex relationship

106 between MetS and HF, further breaking down into different individual components of MetS. It

107 is important to understand the role of each of the MetS components to develop customized

108 strategies for HF prevention and treatment. We explore the relationship between MetS and its

109 components with HF to determine which individuals will have a greater need for preventive or

110 therapeutic measures aimed at reducing the risk of HF. Recommendations from this study

111 could help in developing strategies and guidelines based on MetS components to alleviate the

112 burden of HF.

113 **Study Design and Methods**

114 **Data sources and study design**

115 This study included patients ages 18 and older who received service from the Marshall Health
116 Network between January 2017 and September 2023. The study population was primarily
117 located in Central and North Central Appalachia which includes the western part of West
118 Virginia, the Southern part of Ohio, and the eastern part of Kentucky. Patients were classified as
119 with or without metabolic syndrome if they met at least 3 of the following 5 conditions:

120 • Insulin Resistance (IR): Average Fasting glucose ≥ 100 mg/dL, HbA1c ≥ 5.7 at any point
121 or receiving drug therapy for hyperglycemia, or type 2 diabetes listed as a billing diagnosis or
122 under the patient's problem list.

123 • Hypertension (HTN): Blood pressure $\geq 130/85$ mm Hg, receiving drug therapy for
124 hypertension, or hypertension listed as a billing diagnosis or under their problem list.

125 • Hypertriglyceridemia (HG): Average Triglycerides ≥ 150 mg/dL, receiving drug therapy
126 for hypertriglyceridemia, or hypertriglyceridemia listed as a billing diagnosis or under their
127 problem list.

128 • Low High-Density Lipoprotein Cholesterol (HDL): Average HDL-C < 40 mg/dL in men
129 or < 50 mg/dL in women, receiving drug therapy for reduced HDL-C or low HDL-C listed as a
130 billing diagnosis, or under their problem list.

131 • Obesity: Average BMI > 30 , obesity listed as a billing diagnosis, or under their problem
132 list.

133 This retrospective case-control study has 121 HF cases. The equivalent control subjects were
134 identified by matching age, gender, and heart disease history in the ratio of 1:3 using the nearest
135 neighbor propensity score matching method. The patient data relevant to the study was
136 extracted from Marshall Health Network's Data Warehouse. The study variables are listed
137 below:

- 138 1. Demographic variables – Current Age and Gender
- 139 2. Body Mass Index (BMI)
- 140 3. Family history of ischemic heart disease (IHD) – patients with a family history of
141 ischemic heart disease and other circulatory diseases.
- 142 4. History of MI
- 143 5. Social History (Tobacco and Alcohol use) – The use of any kind of tobacco, including
144 smoking, or alcohol during the study period.
- 145 6. Inherited syndromes – whether the patient had a history of sickle cell disease, Graves'
146 disease, or sleep apnea.
- 147 7. History of Coronary Artery Disease (CAD)
- 148 8. Presence or absence of Insulin Resistance, Hypertension, Low HDL,
149 Hypertriglyceridemia, and Obesity
- 150 9. The number of MetS criteria met by the patient
- 151 10. Metabolic Syndrome (MetS) – Patients who met 3 or more of the 5 conditions mentioned
152 above in variable 8 were classified as patients with MetS
- 153 11. Status of HF

154 This study was approved by Marshall University IRB (FWA 00002704).

155 **Statistical Approach**

156 In this retrospective case-control study, we implemented the nearest neighbor propensity score
157 method to match the 121 HF cases with 363 control subjects that did not have HF. The cases
158 were matched by age, gender, and heart disease history.

159 The descriptive summaries were presented as mean \pm SE for the continuous variables and
160 frequency (percent) \pm SE for the categorical variables. The odds of HF among individuals who
161 met the criteria for MetS and other components were individually calculated. We investigated
162 how MetS components—IR, low HDL, HTN, and HG—individually and simultaneously
163 impacted the risk of HF by using logistic regression models after adjusting for other risk factors
164 (covariates) of HF. This ensures which components of MetS contributed to the higher risk of HF
165 when taken collectively. Once the important components were identified, we compared the risk
166 of HF among the individuals who had those components and their combinations against the
167 other components. In our analyses, HF status was the outcome variable, while MetS status—
168 comprising HTN, HG, HDL, and combinations of previously identified significant components,
169 each taken separately—served as the primary predictor variables. These results were further
170 validated by running logistic regressions of HF on the number of MetS components to assess for
171 an incremental increase in risk upon adding components. In the analyses, we controlled the
172 other variables: age, gender, history of tobacco and alcohol use, history of CAD, and inherited
173 syndromes.

174 All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). The
 175 results were considered statistically significant when the p-values were less than 0.05.

176 **Results**

177 Table 1 presents the distribution of demographic and other controlled variables together with
 178 individual MetS components of 484 individuals. In the study population, the median age was 56
 179 years while the average BMI was 39.9 indicating an obese population, 72.3% of the population
 180 was overweight or obese. There were more males (54.7%) than females (45.3%). 70.3% of
 181 individuals were younger than 50, 19.4% were between 50 and 65, and 10.3% were older than
 182 65. On average, 2.2 MetS criteria were met, and 44.2% of patients met MetS criteria. Most
 183 patients showed obesity, HTN, and IR symptoms, and only 14.1% reported either low HDL or
 184 high HG. 49.2% had some history of tobacco or alcohol use, 33.7% had previous MIs, 55.5% had
 185 a family history of MI and 31.1% had inherited syndromes associated with HF. As the MetS
 186 components occurred collectively, their individual existence was low (table 1). Due to the small
 187 sample, we could not estimate the individual effect of these components alone on HF.

Table 1: Descriptive Summary

Variables	Mean (SE)	Variables	Mean (SE)
Total Sample	484	Total Sample	484
Age (in yrs.)	54.2(0.78) Median=56	Gender	
BMI	39.9(2.47)	Male	257(54.7%)
No. of MetS Criteria Met	2.2(0.05) Median=2	Female	213(45.3%)
		Age Group	
	N (%)	< 50 yrs.	340(70.3%)
HF		50-65 yrs	94(19.4%)
Yes	121(25%)	>=65 yrs.	50(10.3%)
No	363(75%)	Weight Category	

MetS	Yes	214(44.2%)	Obese	297(81.4%)	
	No	270(55.8%)		Overweight	53(14.5%)
No. of MetS Components			Alcohol or Tobacco use (current or past)	Others	15(4.1%)
	0	32(6.6%)			Yes
	1	79(16.3%)	No	246(50.8%)	
	2	159(32.9%)	Inherited Syndromes	Yes	152(31.4%)
	3	174(36%)		No	332(68.6%)
	4	38(7.9%)		History of MI	Yes
5	2(0.4%)	No			321(66.3%)
IR	Yes	330(68.2%)	Family History of Heart MI		
	No	154(31.8%)	Yes	268(55.4%)	
HDL	Yes	7(1.5%)	No	216(44.6%)	
	No	477(98.6%)			
HTN	Yes	386(79.8%)			
	No	98(20.3%)			
HG	Yes	61(12.6%)			
	No	423(87.4%)			
IR Only	Yes	13(2.7%)			
	No	471(97.3%)			
HDL Only	Yes	0(0.0%)			
	No	484(100.0%)			
HTN Only	Yes	30(6.2%)			
	No	454(93.8%)			
HG Only	Yes	1(0.0%)			
	No	483(100.0%)			
Obese Only	Yes	35(7.2%)			
	No	449(92.8%)			

SE- Standard error

188

189 Table 2a presents the odds of HF among patients with different components of MetS except for
 190 low HDL as there was not enough data to evaluate. MetS had a significantly higher risk of HF,
 191 and MetS components IR and HTN also had a significantly higher risk of HF. Obesity had some
 192 protective effect on HF while the effect of HG was not significant. In all estimations, the
 193 covariates mentioned above were controlled to account for their effect on HF status. HF risk is
 194 highest among patients with HTN, they had 6.2 times the odds of HF compared to no HTN.
 195 Among all patients with HF and HTN, almost 80% were attributable to HTN. Similarly, the
 196 odds of HF were 300% higher among patients with IR compared to the patients without, and
 197 almost 70% of HF cases in this group were attributable to IR. The odds of HF are twice as high
 198 in the MetS group compared to those without MetS. Additionally, the attributable risk of HF
 199 due to MetS was 44.3%. Obesity appeared to have a protective effect on HF, the prevention
 200 fraction of HF among these individuals was 62.4%.

Table 2a: Logistic regression analysis of Heart Failure on different Metabolic Syndrome components

	<u>Heart Failure</u>		OR (95% CI)	AR% or Prevention Fraction	P-value	
	Yes	No				
MetS						
	Yes	71(33.2%)	143(66.8%)	2(1.2, 3.1)	44.3	0.005
	No	50(18.5%)	220(81.5%)			
IR						
	Yes	106(32.1%)	224(67.9%)	4(2.2, 7.5)	69.8	<0.001
	No	15(9.7%)	139(90.3%)			
HTN						
	Yes	115(29.8%)	271(70.2%)	6.2(2.4, 16.2)	79.5	<0.001
	No	6(6.1%)	92(93.9%)			
HG						

	Yes	15(24.6%)	46(75.4%)	0.8(0.4, 1.5)	-	0.499
	No	106(25.1%)	317(74.9%)			
HDL**	Yes	3(42.9%)	4(57.1%)	NA	42.4	NA
	No	118(24.7%)	359(75.3%)			
Overweight/Obese				0.2(0.1, 0.6)	62.4	0.004
	Yes	88(25.1%)	262(74.9%)			
	No	10(66.7%)	5(33.3%)			

NA- Not enough samples to evaluate

201
 202 We estimated the effect of more than one component of MetS on HF in Table 2b. We observed
 203 that HTN and IR together had a significant risk of HF, the odds of HF among those who had IR
 204 and HTN was 7.7 times compared to those who didn't have any reported MetS components. In
 205 all HF cases among the patients who had IR and HTN, almost 82% were attributable to IR and
 206 HTN only. The addition of obesity and other factors in the combination of IR and HTN did not
 207 increase the odds of HF at a significant rate. Among patients with obesity who also had IR and
 208 HTN, the odds of HF were 7.9 times with 81.8% attributable risk compared to those who didn't
 209 have any reported MetS. Due to the observed protective effect of both HG and obesity, the odds
 210 of HF among individuals with these components were slightly less than 80%. Also, all other
 211 combinations had insufficient data to evaluate the significance.

Table 2b: Logistic regression analysis of HF on individual MetS combinations

		Heart Failure			AR% or	P-
		Yes	No	OR	Prevention	value
					Fraction	
IR and HTN only					81.5	
	Yes	33(34%)	64(66%)	7.7(1.7,34.4)		0.002
	None	2(6.3%)	30(93.8%)			
IR, HTN, and Obesity					81.8	

only	Yes	55(34.6%)	104 (65.4%)	7.9(1.8,34.4)	0.001
	None	2(6.3%)	30 (93.8%)		
IR, HTN, HG, and Obesity only				78.0	
	Yes	10(28.6%)	25(71.4%)	6(1.2,30)	0.017
	None	2(6.3%)	30(93.8%)		

212

213 We justified the above findings by investigating the effect of metabolic syndrome components

214 on HF. Table 3 shows the additive effect of metabolic syndrome symptoms on HF.

Table 3: Logistic regression of HF on total number of MetS components

Heart Failure

	Yes	No	OR (95% CI)	AR%	P-value
At least one					
Yes	119(26.3%)	333(73.7%)	5.4(1.2, 22.8)	76.0	0.023
None	2(6.3%)	30(93.8%)			
At least two					
Yes	111(29.8%)	262(70.2%)	6.4(1.2, 27)	78.9	0.012
None	2(6.3%)	30(93.8%)			
At least three					
Yes	71(33.2%)	143(66.8%)	7.4(1.2, 32)	81.0	0.007
None	2(6.3%)	30(93.8%)			
At least four**					
Yes	12(30.0%)	28(70.0%)	6.4(1.2, 31.3)	79.0	0.021
None	2(6.3%)	30(93.8%)			

** Not enough data to evaluate

215

216 The odds of HF had increased as the number of MetS components increased. The odds of HF

217 with at least one MetS components was 5.4 times (*P* value=0.023) compared to individuals with

218 no components. Similarly, individuals with at least 2 and at least 3 MetS components had odds

219 of HF was 6.4 and 7.4 times, respectively, compared to those with no reported MetS. There were

220 few individuals with at least 4 components; among these individuals, 79% of the risk of HF was
221 solely attributable to at least 4 MetS components.

222 **Discussion**

223 We explored the relationship between MetS and its components with HF which could provide
224 personalized HF screening, preventive, and treatment options for patients with HF. Overall,
225 insulin resistance and hypertension were the most important components of MetS that could
226 collectively increase the risk of HF. MetS and its components—IR, HTN, and obesity—were
227 significant risk factors for HF. Most patients had multiple components present, so the risk of
228 individual effects could be confounding. Instead, we collectively analyzed the components: the
229 patients with IR and HTN had a higher risk compared to those with at least one other
230 component—HG, obesity, or HTN. There is an increased risk of developing HF as the number
231 of metabolic components increases.

232 Our findings were in line with past research studies while also generating some novel results.
233 Several studies established the relationship between MetS and HF and indicated the increased
234 HF risk among patients with MetS²²⁻²³. Our results also identified MetS as an important risk
235 factor for HF. We identified HTN as the most significant contributing factor to HF risk, which
236 can be correlated to a physiologic basis as follows. Hypertension increases left ventricular
237 afterload and peripheral vascular resistance, leading to pressure and volume-mediated left
238 ventricle remodeling²⁴. This remodeling results in diastolic dysfunction, which is often the first
239 sign of increased load. Chronic hypertension, involving both pressure and volume overloads,
240 can lead to either concentric or eccentric left ventricular hypertrophy, associated with heart

241 failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF),
242 respectively ²⁴.

243 Diabetes is another important risk factor for HF. IR, the primary endocrine dysfunction
244 of diabetes, disrupts glucose uptake and utilization by cardiomyocytes, leading to energy
245 deficits and impaired contractility²⁵. This metabolic inflexibility generates reactive oxygen
246 species and induces mitochondrial dysfunction ²⁶. The pathophysiology of diabetes-associated
247 HF involves several key mechanisms. Elevated hemoglobin A1c (HbA1c) levels are associated
248 with an increased risk of HF. Hyperglycemia leads to the formation of advanced glycation end-
249 products and the modification of proteins by β -N-acetylglucosamine, which can negatively
250 impact cardiac function ²⁷. Systemic inflammation observed in patients with diabetes likely
251 contributes to cardiac complications. Autonomic dysfunction, disturbances in myocardial
252 metabolism, cardiac remodeling, and poor perfusion are additional mechanisms of diabetes-
253 induced HF²⁸.

254 We were not able to isolate the effects of individual components due to the size limitations as
255 these conditions were rarely observed as a single factor in our study population. However, we
256 found that both HG and low HDL levels were independently associated with an increased risk
257 of HF. Atherogenic dyslipidemia induced by HG and low HDL promotes endothelial
258 dysfunction and atherosclerosis, compromising coronary blood flow and explaining our finding
259 pathologically ²⁹.

260 We observed a protective effect of obesity on HF. This may be due to our choice of measurement
261 unit for obesity-BMI. Individuals with obesity often have preserved skeletal muscle mass and

262 may have a better prognosis secondary to increased stroke volume and thus cardiac output
263 compared with their counterparts who have reduced lean mass and lower stroke volume and
264 cardiac output. Lean mass may play a major role in outcome differences seen in the HF
265 population³⁰.

266 There are several strengths to our study. First, a few studies investigated the relationship
267 between some of the MetS components (IR, HTN) with HF but often did not adjust other risk
268 factors. For most of our analyses, we adjusted for age, sex, BMI, tobacco use, alcohol
269 consumption, family history of HF, and inherited syndromes shown to be related to HF.

270 Second, it is unlikely to observe just a single component of MetS; it is important to study the
271 simultaneous effect of these components on HF. We investigated the additive effects of
272 metabolic components on HF and compared the risks of HF between patients with MetS and its
273 components. Our study is the first to focus on studying the additive effect of individual
274 metabolic syndrome components.

275 Third, we performed the risk analysis based on the number of components (table 3) and found
276 the increased odds of HF as the number of components increased, which is a novel finding.

277 This study also has some limitations. First, the analysis was limited to mainly Central and North
278 Central Appalachia, which may affect the generalizability of the study findings. However, the
279 identified factors reflect the general pattern for the US population. Second, we could not include
280 race, diet, and lifestyle information in the analyses even though they are significant risk factors
281 for HF^{31,32}. There was less racial diversity in the data due to the demographic structure of this
282 region, with more than 90% of the population being White³³. Future research on HF should

283 consider adding these factors with other factors such as health beliefs, attitude toward HF
284 screening and early detection, lifestyle, and SES as they relate to the disease etiology.
285 Furthermore, we could not perform subgroup analyses by age and gender due to data
286 limitations, so we controlled them in our analyses.
287 Metabolic syndrome, and its components, insulin resistance, hypertension, and obesity were
288 significant risk factors of HF. Multiple components are often present, and individuals with HTN
289 and IR had a significantly higher risk of HF compared to individuals with no components or
290 any other combinations of components. As the number of MetS components increases, and for
291 individuals with HTN and IR, treatment should be more aggressive for HF prevention
292 compared to those with fewer factors. This will improve the health of our population and
293 combat the marked increase in MetS and HF incidence nationally.

294 **Acknowledgment**

295 We acknowledge the Translational Sciences Core of COBRE/ACCORD, Clinical, and
296 Translational Sciences Department, Joan C Edwards School of Medicine, Marshall University for
297 analytics support.

298 **References**

- 299 1. National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER
300 Database. Accessed February 2, 2024.
- 301 2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2023 Update:
302 A Report From the American Heart Association. *Circulation*. 2023;147:e93–e621.
- 303 3. Virani SS, Alonso A, Benjamin EJ, et al. On behalf of the American Heart Association
304 Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics
305 Subcommittee. Heart Disease and Stroke Statistics—2020 Update: A Report From the

- 306 American Heart Association. *Circulation*. 2012;141(9).
307 <https://doi.org/10.1161/CIR.0000000000000757>.
- 308 4. Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic
309 review and meta-analysis. *Diabetes Care*. 2012; 35(11):2402–2411. doi: 10.2337/dc12-0336.
- 310 5. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with
311 the metabolic syndrome: a summary of the evidence. *Diabetes Care*. 2005; 28(7):1769–1778.
312 doi: 10.2337/diacare.28.7.1769.
- 313 6. Watanabe S, Yaginuma R, Ikejima K, et al. Liver diseases and metabolic syndrome. *J*
314 *Gastroenterology*. 2008; 43, 509. <https://doi.org/10.1007/s00535-008-2193-6>.
- 315 7. Raikou VD, & Gavriil S. Metabolic Syndrome and Chronic Renal Disease. *Diseases*. 2018 Jan
316 24;6(1):12. doi: 10.3390/diseases6010012.
- 317 8. Ritchie SA, & Connell JMC. The link between abdominal obesity, metabolic syndrome and
318 cardiovascular disease. *Nutrition, Metabolism & Cardiovascular Diseases*. 2007;17,319e326.
- 319 9. Shin JA, Lee JH, Lim SY, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its
320 clinical interpretations and usefulness. *J Diabetes Investig*. 2013 Jul 8;4(4):334-43. doi:
321 10.1111/jdi.12075.
- 322 10. National Institute of Health. What is Metabolic Syndrome? Accessed February 10, 2024.
- 323 11. Burger, P. M., Koudstaal, S., Dorresteijn, J. A. N., et al. Metabolic syndrome and risk of
324 incident heart failure in non-diabetic patients with established cardiovascular disease.
325 *International Journal of Cardiology*, 2023;379, 66–75. <https://doi.org/10.1016/j.ijcard.2023.03.024>
- 326 12. Grundy, S. M. Obesity, Metabolic Syndrome, and Cardiovascular Disease. *The Journal of*
327 *Clinical Endocrinology & Metabolism*. 2004;89(6), 2595–2600. [https://doi.org/10.1210/jc.2004-](https://doi.org/10.1210/jc.2004-0372)
328 0372
- 329 13. Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow R. The role of
330 metabolic syndrome in heart failure. *European Heart Journal*, 2015;36(39), 2630–2634.
331 <https://doi.org/10.1093/eurheartj/ehv350>
- 332 14. Purwowiyoto S. L. & Prawara A. S. Metabolic syndrome and heart failure: Mechanism and
333 management. *Medicine and Pharmacy Reports*. 2021;94(1), 15–21. [https://doi.org/10.15386/mpr-](https://doi.org/10.15386/mpr-1884)
334 1884
- 335 15. Ebong IA, Goff DC Jr, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in
336 obesity. *Obes Res Clin Pract*. 2014 Nov-Dec;8(6):e540-8. doi: 10.1016/j.orcp.2013.12.005.
- 337 16. Yang CD, Pan WQ, Feng S, et al. Insulin Resistance Is Associated With Heart Failure With
338 Recovered Ejection Fraction in Patients Without Diabetes. *J Am Heart Assoc*. 2022 Oct
339 4;11(19):e026184. doi: 10.1161/JAHA.122.026184
- 340 17. Appalachian Regional Commission. Health Disparities in Appalachia. Accessed February
341 19, 2024.
- 342 18. Appalachian Regional Commission. Rural Appalachia Compared to the Rest of Rural
343 America. Accessed February 19, 2024.
- 344 19. Appalachian Regional Commission. Creating a Culture of Health in Appalachia: Disparities
345 and Bright Spots- Health Care Systems. Accessed February 24, 2024.

- 346 20. Cardarelli K, Westneat S, Dunfee M, May B, Schoenberg N, Browning S. Persistent
347 disparities in smoking among rural Appalachians: Evidence from the Mountain Air Project.
348 *BMC Public Health*. 2021;21(1), 270. <https://doi.org/10.1186/s12889-021-10334-6>
- 349 21. Herath J, & Brown, C. (2013). An Analysis of Adult Obesity and Hypertension in
350 Appalachia. *Global Journal of Health Science*. 2013;5(3), 127–138.
351 <https://doi.org/10.5539/gjhs.v5n3p127>.
- 352 22. Gargiulo P, Marsico F, Renga F, et al. The metabolic syndrome in heart failure: insights to
353 specific mechanisms. *Heart Fail Rev*. 2020 Jan;25(1):1-7. doi: 10.1007/s10741-019-09838-6.
- 354 23. Arcopinto M, Schiavo A, Salzano A, et al. Metabolic Syndrome in Heart Failure: Friend or
355 Foe? *Heart Fail Clin*. 2019 Jul;15(3):349-358. doi: 10.1016/j.hfc.2019.02.004.
- 356 24. Du Cailar G, Pasquie JL, Ribstein J, Mimran A. Left ventricular adaptation to hypertension
357 and plasma renin activity. *J Hum Hypertens*. 2000;14:181–188. doi: 10.1038/sj.jhh.1000974.
- 358 25. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen
359 deposition may contribute to the deterioration of systolic function in hypertensive patients
360 with heart failure. *J Am Coll Cardiol*. 2006;48:89–96. doi: 10.1016/j.jacc.2006.01.077.
- 361 26. Liu M, Lv J, Pan Z, Wang D, Zhao L, Guo X. Mitochondrial dysfunction in heart failure and
362 its therapeutic implications. *Frontiers in Cardiovascular Medicine*. 2022;9, 945142.
363 <https://doi.org/10.3389/fcvm.2022.945142>
- 364 27. Prakoso D, De Blasio MJ, Qin C, et al. Phosphoinositide 3-kinase (p110 alpha) gene delivery
365 limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model
366 with established diastolic dysfunction. *Clin Sci (Lond)*. 2017; 131: 1345.
- 367 28. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms
368 and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol Ther*.
369 2014; 142: 375.
- 370 29. Grundy, SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin
371 resistance. *Clinical Cornerstone*. 2006;8 Suppl 1, S21-27. [https://doi.org/10.1016/s1098-](https://doi.org/10.1016/s1098-3597(06)80005-0)
372 [3597\(06\)80005-0](https://doi.org/10.1016/s1098-3597(06)80005-0)
- 373 30. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on
374 coronary blood flow in patients with diabetes mellitus. *Circulation*. 1999; 100: 813.
- 375 31. Billingsley HE, Hummel SL, Carbone S. The role of diet and nutrition in heart failure: A
376 state-of-the-art narrative review. *Prog Cardiovasc Dis*. 2020 Sep-Oct;63(5):538-551. doi:
377 10.1016/j.pcad.2020.08.004.
- 378 32. Larsson SC, Tektonidis TG, Gigante B, Akesson A, Wolk A. Healthy Lifestyle and Risk of
379 Heart Failure. *Circulation*. 2016; 9 (4).
380 <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002855>.
- 381 33. Pollard K, Jacobsen LA. The Appalachian region: A data overview from the 2008–2012
382 American community survey chartbook. *PRB*. 2014.